Tromsø, Norway - November 21, 2024 - ArcticZymes Technologies ASA (OSE: AZT), is
proud to highlight the exceptional performance of our M-SAN HQ nuclease in the
purification of recombinant measles viruses (MV), as detailed in a recent
publication in the Journal of Chromatography A. The study demonstrates how
integrating M-SAN HQ nuclease with heparin affinity chromatography streamlines
MV purification, achieving unmatched levels of both purity and yield.

Innovative Approach to MV Purification

The study, titled "Highly Pure Measles Virus Generated by Combination of Salt
-Active Nuclease Treatment and Heparin Affinity Chromatography," by Mayer et al.
addresses the challenges of purifying fragile, enveloped viruses like MV.
Traditional methods often involve multiple steps, risking viral loss and reduced
yields. By combining M-SAN HQ nuclease treatment with heparin affinity
chromatography, researchers achieved a simplified workflow that enhances both
purity and recovery rates.

Key Findings

  · Enhanced Purity: The integrated approach effectively removes host-cell DNA
and proteins, resulting in highly pure MV preparations.
  · Increased Yield: The streamlined process minimizes viral loss, leading to
higher recovery rates compared to conventional methods.
  · Workflow Simplification: The combination reduces the number of purification
steps, decreasing processing time and complexity.

Why This Matters

In the development of vaccines, gene therapies, and oncolytic treatments,
manufacturers know that ensuring product purity is critical to meeting stringent
regulatory standards and safeguarding patient safety. Host cell DNA
contamination, a common challenge in viral vector production, must be reduced to
levels below the FDA threshold of 10 ng/dose to ensure compliance and
therapeutic efficacy. Traditional nucleases, included in the study, struggle to
consistently meet these standards without adding complexity and cost, e.g.
additional filtration, to the purification process.

M-SAN HQ nuclease addresses this challenge head-on, achieving DNA clearance far
below the 10 ng/dose while also maintaining exceptionally high recovery of virus
particles. This unique combination of performance and efficiency enables
manufacturers to streamline their workflows, reduce the need for additional
purification steps, and improve overall production yields.

For patients, this means faster access to safe, effective therapies